Roth Restarts Cytokinetics (CYTK) at Buy; Get in Now Ahead of April '14 ALS Data
Tweet Send to a Friend
Roth Capital is restarting Cytokinetics, Inc. (Nasdaq: CYTK) at Buy with a price target of $25.
Analyst Joseph Pantginis ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Analyst Joseph Pantginis ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
